Cargando…
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are exquisitely sensitive to EGFR tyrosine kinase inhibitors (TKIs). Despite the efficacy and superiority of EGFR TKIs over che...
Autores principales: | Cortot, Alexis B., Jänne, Pasi A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487318/ https://www.ncbi.nlm.nih.gov/pubmed/25176972 http://dx.doi.org/10.1183/09059180.00004614 |
Ejemplares similares
-
Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma
por: Zhu, You-Cai, et al.
Publicado: (2019) -
Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016) -
Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus
por: Okuma, Yusuke, et al.
Publicado: (2014) -
Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: ‘PRIDE’ Complex
por: Madke, Bhushan, et al.
Publicado: (2014) -
E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis
por: Chang, Yu-Ping, et al.
Publicado: (2023)